News
BDX
241.02
+1.55%
3.68
Goldman Sachs Maintains Buy on Becton, Dickinson, Lowers Price Target to $272
Benzinga · 6d ago
Goldman Sachs Adjusts Becton, Dickinson and Co.'s Price Target to $272 From $319, Keeps Buy Rating
Goldman Sachs Adjusts Becton, Dickinson and Co.'s Price Target to $272 From $319, Keeps Buy Rating
MT Newswires · 11/23 11:14
Are Becton, Dickinson and Company's (NYSE:BDX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
With its stock down 17% over the past three months, it is easy to disregard Becton Dickinson (NYSE:BDX). But if you pay...
Simply Wall St. · 11/18 12:01
BD to Present at Evercore ISI 5th Annual HealthCONx Conference
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present virtually at the Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022 at 8:00 am Eastern Time.
PR Newswire · 11/15 21:15
Becton Dickinson (NYSE:BDX) Is Paying Out A Larger Dividend Than Last Year
Becton, Dickinson and Company's ( NYSE:BDX ) dividend will be increasing from last year's payment of the same period to...
Simply Wall St. · 11/13 13:30
NIO To $34? Plus This Analyst Sees $245 For Becton, Dickinson and Company
Benzinga · 11/11 16:00
Selling US$1.1m worth of stock earlier this year was a lucrative decision for Becton, Dickinson and Company (NYSE:BDX) insiders
Becton, Dickinson and Company's (NYSE:BDX) stock rose 3.7% last week, but insiders who sold US$1.1m worth of stock over...
Simply Wall St. · 11/11 13:00
--Piper Sandler Adjusts Becton, Dickinson and Co.'s Price Target to $245 From $255, Keeps Neutral Rating
--Piper Sandler Adjusts Becton, Dickinson and Co.'s Price Target to $245 From $255, Keeps Neutral Rating
MT Newswires · 11/11 11:29
Piper Sandler Maintains Neutral on Becton, Dickinson, Lowers Price Target to $245
Benzinga · 11/11 11:28
$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,700 Today
Benzinga · 11/10 21:34
Becton Dickinson expects fiscal 2023 COVID test sales to drag
Reuters · 11/10 15:43
Becton Dickinson's FY23 Guidance Trails Wall Street View Reflecting Foreign Currency Impact
Benzinga · 11/10 13:59
BRIEF-BD Reports Fourth Quarter Financial Results
Reuters · 11/10 12:59
BRIEF-Bd Board Increases Dividend For 51St Consecutive Year
Reuters · 11/10 12:38
Becton, Dickinson sets FY23 outlook below consensus amid currency headwinds
Seekingalpha · 11/10 12:08
Becton, Dickinson reports Q3 earnings beat; issues FY23 guidance
Seekingalpha · 11/10 11:34
Becton Q4 EPS Adj $2.75 Beats $2.74 Estimate, Sales $4.76B Beat $4.72B Estimate
Benzinga · 11/10 11:32
Becton, Dickinson raises dividend by ~5% to $0.91/share
Seekingalpha · 11/10 11:29
Earnings Scheduled For November 10, 2022
Benzinga · 11/10 09:23
Research Alert: CFRA Maintains Hold Opinion On Shares Of Becton, Dickinson And Company
Research Alert: CFRA Maintains Hold Opinion On Shares Of Becton, Dickinson And Company
MT Newswires · 11/10 08:24
More
Webull provides a variety of real-time BDX stock news. You can receive the latest news about Becton Dickinson & Co through multiple platforms. This information may help you make smarter investment decisions.
About BDX
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through three business segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.